Comparative evaluation of eravacycline susceptibility testing methods in 587 clinical carbapenem-resistant Acinetobacter baumannii isolates: broth microdilution, MIC test strip and disc diffusion
Journal of Antimicrobial Chemotherapy · 2025
DOI: 10.1093/jac/dkae426 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Journal of Antimicrobial Chemotherapy, 2025. Verfasst von Qihui Liu und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious Diseases, Shanghai Key Laboratory of Infectious Diseases and Biosafety Emergency Response, National Medical Center for Infec…. Hauptthemen laut MEDLINE: Acinetobacter baumannii, Anti-Bacterial Agents, Carbapenems, Tetracyclines. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 23 Literaturangaben. Gefördert von: National Key Clinic Specialized Subject Project of China.
Abstract (Originalsprache)
Objectives
The study aimed to evaluate the accuracy of different methods for determining carbapenem-resistant Acinetobacter baumannii (CRAB) susceptibility to eravacycline.
Methods
We collected 587 CRAB strains from Huashan Hospital affiliated to Fudan University between 2019 and 2023. The broth microdilution (BMD) method served as the reference standard. The susceptibility results were evaluated using the clinical breakpoints established by the Chinese Committee on Antimicrobial Susceptibility Testing (ChinaCAST) (susceptible MIC, ≤ 1 mg/L; inhibition zone diameter, ≥ 15 mm). The study compared the reliability of the MIC test strip (MTS) and disc diffusion (DD) methods in detecting CRAB susceptibility to eravacycline.
Results
The MICs required to inhibit 50% and 90% of CRAB growth were as follows: BMD, 0.5/1 mg/L; MTS, 0.38/0.75 mg/L. According to the ChinaCAST breakpoints, the BMD method demonstrated a 98.13% (576/587) susceptibility rate, whereas the MTS and DD methods showed susceptibility rates of 97.96% (575/587) and 97.61% (573/587), respectively. The essential agreement rate between the MTS and BMD methods was 94.55%. Categorical agreement (CA) rates for the MTS and DD methods were 99.83% and 99.49%, respectively. The major error (ME) rate for MTS was 0.17%, with no very major errors (VMEs) observed. For the DD method, the ME rate was 0.51%, also with no VMEs.
Conclusion
The MTS and DD methods demonstrated strong consistency with the BMD reference method, with CA, ME and VME rates meeting methodological evaluation criteria. Both MTS and DD methods are reliable alternatives for assessing the antibacterial activity of eravacycline in clinical microbiology laboratories.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Infectious Diseases, Shanghai Key Laboratory of Infectious Diseases and Biosafety Emergency Response, National Medical Center for Infectious Diseases, Huashan Hospital, Shanghai Medical College, Fudan Univ…
- Department of Laboratory Medicine, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai 200040, China.
Förderung
- National Key Clinic Specialized Subject Project of China
Zitieren
APA
Liu, Q., Li, S., Wang, X., Lin, Y., Jiang, H., & Li, N. (2025). Comparative evaluation of eravacycline susceptibility testing methods in 587 clinical carbapenem-resistant Acinetobacter baumannii isolates: broth microdilution, MIC test strip and disc diffusion. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkae426
Vancouver
Liu Q, Li S, Wang X, Lin Y, Jiang H, Li N. Comparative evaluation of eravacycline susceptibility testing methods in 587 clinical carbapenem-resistant Acinetobacter baumannii isolates: broth microdilution, MIC test strip and disc diffusion. Journal of Antimicrobial Chemotherapy. 2025. doi:10.1093/jac/dkae426
BibTeX
@article{Liu2025,
author = {Liu, Qihui and Li, Shirong and Wang, Xuan and Lin, Yijing and Jiang, Haoqin and Li, Ning},
title = {Comparative evaluation of eravacycline susceptibility testing methods in 587 clinical carbapenem-resistant Acinetobacter baumannii isolates: broth microdilution, MIC test strip and disc diffusion},
journal = {Journal of Antimicrobial Chemotherapy},
year = {2025},
doi = {10.1093/jac/dkae426}
}
EUVIMED